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While it is now fully recognised that grey matter (GM) lesions are at least as abundant as 
white matter lesions in multiple sclerosis (MS), it is hard to imagine that it was only a decade 
ago that the first deliberate attempt was made to visualize GM lesions with magnetic 
resonance imaging (MRI). An initial study showed that using conventional T2-weighted and 
3D fluid-attenuated inversion recovery (FLAIR) imaging, only ~5% of GM lesions were 
detected, [1] and this disappointing finding spurred the development of MRI techniques that 
would improve on this. Soon after, double inversion recovery (DIR) - which suppresses 
signals from both cerebrospinal fluid and white matter, making GM more conspicuous - was 
applied to solve this sensitivity problem, and proved superior to both FLAIR and T2 in 
detecting cortical GM lesions.[2] However, DIR images often exhibit artefacts that can be 
mistaken for GM lesions, for example small vascular structures or incompletely suppressed 
fluid in Virchow-Robin spaces posed a problem. A MAGNIMS study group produced 
consensus criteria to facilitate reliable identification of GM lesions on DIR images,[3] and 
using these criteria in a post-mortem study, pathological specificity was shown to be high 
(90%) but sensitivity lingered around a disappointing 20%.[4] So further techniques - aiming 
to either complement or replace DIR - were tried. 3D-T1 based techniques,[5] T2*-weighted 
imaging,[6] phase-sensitive inversion recovery (PSIR),[7] and creative combinations of all 
of the above were investigated. Whether or not any of these techniques should be 
considered ‘better than the other’ remains open to debate, given the often imperfect 
conditions of comparison, but, importantly, all of them still show only the tip of the proverbial 
iceberg.8 
 
Following this, researchers turned to higher field-strengths to further improve cortical lesion 
detection in MS. With better spatial resolution, sensitivity for cortical demyelination increased 
from 20% when using DIR at standard clinical field-strengths[4] to 30-50% with T2(*)-
weighted imaging at 7T.[9-11] But this still means that at least half of the total number of 
cortical lesions are missed. Reflexively, we feel that we should improve this state of affairs; 
invest more research time and funds into further development of MRI techniques, higher-
fields, or both. But it might be good to pause for a moment and ask ourselves to what end 
would we act upon this reflex. For one, conventional imaging (e.g. T2-weighted and FLAIR 
scans) used to detect white matter lesions, has served us well in diagnostic criteria and in 
treatment trials, yet still only detects between 60 and 70% of such lesions.[1] 
 
In general, a number of clinical reasons for further improving cortical lesion visualization with 
MRI could be thought of: greater diagnostic accuracy, more robust prognostication, or better 
monitoring of therapeutic effects. So far, studying cortical lesions at clinical (1.5T and 3T) 
field-strengths has indeed resulted in a solid body of evidence showing an association 
between cortical lesions and disability, including cognitive impairment.[12] Taking cortical 
lesions into account appears to increase the diagnostic accuracy of MRI criteria[13] and has 
prognostic value.[14] The presence of cortical pathology also helps distinguish between MS 
and its mimics.[15] However, the question is whether or not visualizing more cortical lesions 
in MS patients will really make any further difference? We already know that the tip is 
representative of the whole iceberg.4 Unless, of course, the type of lesions that we currently 
see on MRI is different from the type of lesions that remain obscure. And, granted, that 
seems to be the case. Even at ultra-high field-strength (7T), despite being the most 
abundant type, subpial GM lesions are rarely seen.[9] This could be seen as a problem for 
those of us arguing that there is no compelling reason to further improve GM lesion 
visualization. However, there is no convincing evidence that subpial lesions are 
pathologically distinct or more (or differentially) clinically eloquent than the other types of 
cortical lesion that we do see more readily on MRI. 
 
  
Correlations between cortical lesions and clinical deficits are certainly present but they are 
modest. Realising this need not drive us to improve our measurement simply to be able to 
confirm correlations in smaller cohorts. Instead, in a complex, multifactorial disease like MS, 
in which multiple different pathologies may be clinically relevant, perhaps we should aim to 
explain clinical variance better by integrating measures of these different pathologies rather 
than focusing on just one. 
 
Of course, a different reason for wanting to improve cortical lesion visibility on MRI may be 
entirely scientific. For example, for the insights we may gain into the mechanisms underlying 
MS pathology or to provide more reliable measures of treatment efficacy. Here again, a case 
could be made for better detecting subpial lesions, as it is not clear that the genesis of all 
types of cortical lesions is the same. However, as long as what we see is in direct proportion 
to what we do not, the actual proportion seen may not be quite so important. Instead, 
improving the reliability of measures may be more relevant. With this in mind, rather than 
trying to improve visualisation of GM lesions by feverishly developing new MRI methods, a 
more cost efficient option should probably be tried first. Recent work provided a clue as to 
what can be done to improve lesion detection while using already existing methodology. 
Jonkman et al. (2015)[10] compared 7T T2*-weighted MRI with histopathology findings, and 
showed that although prospective scoring (i.e. without knowing where a lesion was before 
scoring) identified only about 30% of lesions, retrospectively (i.e., after the location of the 
lesion had been revealed) ~85% of lesions were visible. This serves to show that there is 
substantial potential for gains in lesion detection even using the scans already available to 
us, through better training of operators. Now may be a good time to organise an international 
meeting to refine the MAGNIMS consensus criteria for GM lesion marking, originally based 
on DIR, for use with other more recently introduced imaging methods. 
 
In conclusion, although we recognise the potential for further improvement of cortical lesion 
visualisation, we should keep in mind the reasons for doing so and not simply pursue this 
because of the general belief that ‘more must be better’. 
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